We evaluated the in vitro susceptibility of Legionella pneumophila ATCC 33152 (serogroup I) to 13 antibiotics alone and in combination with rifampin (0.1 mg/liter) by three methods. Extracellular susceptibility was determined by MIC determinations and time kill curves in buffered yeast extract broth, while intracellular susceptibility was determined by peripheral human monocytes in RPMI 1640 culture medium. Antibiotic concentrations equal to or greater than the broth dilution MIC inhibited or killed L. pneumophila by-the time kill method, except this was not the case for trimethoprim-sulfamethoxazole. Antibiotic concentrations below the broth dilution MIC did not inhibit Legionella growth. The only antibiotic-rifampin combinations which produced improved killing of L. pneumophila by the time kill method were those in which the logarithmic growth of L. pneumophila occurred during the experiment (rosoxacin, amifloxacin, cinoxacin, trimethoprimsulfamethoxazole, clindamycin, and doxycycline). Neither direct MICs nor time kill curve assays accurately predicted intracellular L. pneumophila susceptibility. Rifampin, erythromycin, ciprofloxacin, rosoxacin, enoxacin, amifloxacin, gentamicin, clindamycin, and doxycycline all inhibited intracellular L. pneumophila growth at readily achievable concentrations in serum. Cefoxitin and thienamycin showed no inhibition of growth, although they were present extracellularly at concentrations that were 20 to 1,000 times their broth dilution MICs. Clindamycin was the only antibiotic that was able to inhibit intracellular L. pneumophila growth at an extracellular concentration below its MIC. The gentamicin (5 mg/liter)-rifampin combination was the only antibiotic-rifampin combination which demonstrated decreased cell-associated Legionella survival in this model of in vitro susceptibility.
enoxacin, amifloxacin, gentamicin, clindamycin, and doxycycline all inhibited intracellular L. pneumophila growth at readily achievable concentrations in serum. Cefoxitin and thienamycin showed no inhibition of growth, although they were present extracellularly at concentrations that were 20 to 1,000 times their broth dilution MICs. Clindamycin was the only antibiotic that was able to inhibit intracellular L. pneumophila growth at an extracellular concentration below its MIC. The gentamicin (5 mg/liter)-rifampin combination was the only antibiotic-rifampin combination which demonstrated decreased cell-associated Legionella survival in this model of in vitro susceptibility. Legionella pneumophila was first described in 1976 after an outbreak of acute respiratory illness in Philadelphia (10) . In early reports, treatment of this illness with beta-lactam antibiotics was generally unsuccessful, while treatment with erythromycin or rifampin was associated with a good clinical response (11) . Since the first defined outbreak, several investigators (17) (18) (19) 24) have shown that L. pneumophila survives intracellularly within human monocytes and macrophages, and it is currently believed that this ability protects it from antibiotics which remain predominantly in the extracellular space. In vitro susceptibility systems should include an evaluation of the intracellular activity of antimicrobial agents against L. pneumophila to be clinically useful. In this experiment we examined the ability of 13 antibiotics alone and in combination with rifampin to inhibit intracellular multiplication of L. pneumophila in peripheral human monocytes, and compared this procedure with susceptibility testing, including time kill curve techniques.
MATERIALS AND METHODS
Preparation of infectious inocula. Virulent L. pneumophila ATCC 33152 (serogroup I) was obtained from the Centers for Disease Control, Atlanta, Ga., was used in all experiments, and was frozen at -70°C until needed. At that time a sample of the strain was plated onto buffered charcoal yeast extract agar (GIBCO Diagnostics, Madison, Wis.) and grown for 48 h at 35°C in room air. After this time, pure colonies of L. pneumophila were placed in buffered yeast extract (BYE) broth (6) and incubated overnight on a gyratory shaker at Time kill curves. The number of CFU/ml expressed over time for control organisms and organisms exposed to rifampin, experimental antibiotic, or experimental antibioticrifampin is given in Fig. 1A to G. As determined by time kill curves, antibiotic activity against cell-free L. pneumophila could be classified into one of three categories.
First, cefoxitin, ciprofloxacin, gentamicin, thienamycin, and erythromycin showed steady decreases in the number of L. pneumophila CFU/ml when compared with controls ( Fig.  1A , C, E, and F). Each drug was present in concentrations equal to or greater than its MIC, as determined in BYE broth (10 and 100 times the cefoxitin, MIC, 13 times the ciprofloxacin MIC, 4 and 12 times the gentamicin MIC, 50 times the thienamycin MIC, and 1.5 times the erythromycin MIC). The combination of rifampin with these antibiotics produced variable results. For cefoxitin, ciprofloxacin, and gentamicin, the rate of killing of L. pneumophila was slightly decreased (Fig. 1A , C, and E). This delayed killing was most apparent for ciprofloxacin and gentamicin (1.56 mg/liter), as 2 additional days were required to achieve comparable reductions of L. pneumophila CFU/ml ( Fig. 1C and E) when rifampin was present. Erythromycin-rifampin, however, did show a greater than 2 log unit decrease in L. pneumophila CFU/ml when compared with erythromycin alone on days 3 and 4 (Fig. 1F) .
The second group contained rifampin, amifloxacin, rosoxacin, and doxycycline. These compared with controls (Fig. 1A , B, and G). Following each transient decrease, logarithmic growth of L. pneumophila occurred. Each of these drugs was present at a concentration equal to or greater than its MIC, as determined in BYE broth (greater than or equal to 50 times the rifampin MIC, 3 times the amifloxacin MIC, 28 times the rosoxacin MIC, and 1 time the doxycycline MIC). The combination of rifampin with each antibiotic produced a greater than 2 log unit decrease in the number of L. pneumophila CFU/ml on days 3 and 4 when compared with either drug alone. Amifloxacin and rosoxacin in combination with rifampin, however, showed slightly delayed killing of L. pneumophila on days 1 and 3, as 1 additional day was required to achieve comparable numbers of L. pneumophila CFU/ml when rifampin was present (Fig.   1B ).
The final group contained cinoxacin, trimethoprim-sulfamethoxazole, and clindamycin. These antibiotics had no effect of L. pneurmophila multiplication (Fig. 1C, D , and G).
Each drug was present at a concentration that was less than or equal to its MIC, as determined in BYE broth (0.2 times (Fig. 1C, D, and G) . No rifampin combination in this group showed a greater than 2 log unit decrease when compared with rifampin alone.
Monocyte experiments. The numbers of cell-associated L. pneumophila organisms in non-antibiotic-containing controls showed logarithmic increases for the first 48 h of incubation (Fig. 2) . Between 48 and 72 h a slower increase occurred, and after 72 h no further increases occurred. When present, antibiotic effects occurred after 24 h and persisted for the remainder of each experiment, as was the case with rifampin. L. pneumophila was not able to reproduce solely in RPMI 1640 medium with 15% fetal bovine serum.
The number of L. pneumophila CFU/ml associated with human mononuclear cells on day 3 is presented in Fig. 3 . Rifampin, erythromycin, ciprofloxacin, rosoxacin, enoxacin, amifloxacin, cinoxacin (15 mg/liter), clindamycin (3.0 mg/liter), doxycycline, gentamicin, and trimethoprim-sulfamethoxazole (0.15/2.9 mg/liter) all exhibited a decrease in the number of cell-associated L. pneumophila CFU/ml below the lower limit of the 99% confidence interval for the control organisms (2.5 x 105 CFU/ml). By contrast, cinoxacin (0.25 and 1.5 mg/liter), clindamycin (1.56 mg/liter), trimethoprim-sulfamethoxazole (0.025/0.5 mg/liter), cefoxitin (0.2, 1.0, and 10.0 mg/liter), and thienamycin (5.0 mg/liter) did not show a decrease outside this limit, although cinoxacin (1.2 times the MIC), cefoxitin (20, 100, and 1,000 times the MIC), and thienamycin (500 times the MIC) were all run at concentrations greater than their MIC, as determined in BYE broth.
Clindamycin at 3.0 mg/liter (0.25 times the MIC) was able to inhibit cell-associated Legionella growth below the lower limit of the 99% confidence interval for control organisms (7.0 x 103 versus 2.5 x 105 CFU/ml). Cinoxacin (0.2 times the MIC) and trimethoprim-sulfamethoxazole (0.17 times the MIC) showed no effect on cell-associated L. pneumophila growth at sub-MIC concentrations. Ciprofloxacin at 3.0 mg/liter (<10 CFU/ml) was the only antibiotic to inhibit cell-associated L. pneumophila growth below the lower limit of the 99% confidence interval for rifampin (1.9 x 101).
The addition of rifampin to each antibiotic (Fig. 4) prim-sulfamethoxazole, and cinoxacin). This growth inhibition was not different than that for rifampin alone. The only combination regimen which fell below the lower limit of the 99% confidence interval for rifampin alone was gentamicin ( 
DISCUSSION
The results of L. pneumophila susceptibility paralleled each other when determined by direct MIC and time kill techniques. Time kill curves which were performed at antibiotic concentrations equal to or greater than the BYE broth dilution MIC generally showed decreases in L. pneumophila CFU when compared with that in controls. Only trimethoprim-sulfamethoxazole failed to inhibit L. pneumophila growth by the time kill curve method when run at its MIC.
Current recommendations for intravenous trimethoprimsulfamethoxazole use suggest administration within 2 h of reconstitution to prevent precipitation of drugs at high doses (27) . To our knowledge, studies of trimethoprim-sulfamethoxazole stability in BYE broth have not been performed. Other antibiotics might have deteriorated during the 4 days over which our experiments were carried out. This factor could explain the increased L. pneumophila growth we observed on days 3 and 4 of the time kill curve experiments when the organisms were incubated with rifampin, amifloxacin, rosoxacin, and doxycycline. No studies on the stability of these antibiotics in BYE broth have been published to date.
The emergence of resistance should also be considered as a possible explanation for the increased L. pneumophila growth we observed on days 3 and 4 of the time kill curve experiments. We have seen rifampin resistance develop during time kill curve experiments with a different strain of L. pneumophila (unpublished data).
For rifampin in combination with ciprofloxacin, amifloxacin, rosoxacin, cefoxitin, and gentamicin, slightly improved survival of L. pneumophila was shown by the time kill curve method, suggesting that there was possible antagonism. DNA transcription may be necessary for these drugs to be most effective. Because rifampin inhibits transcription, it may have decreased the effectiveness of these drugs (29) . Drug inactivation by rifampin is also a consideration. Results of a previous study (15) have shown that rifampin is a significant inactivator of antibiotics through the hepatic enzyme system; however, this is an in vivo phenomenon, and we are not aware of evidence for direct chemical inactivation by rifampin.
In 1980, Horwitz et al. (17) first demonstrated that L. pneumophila multiplies within human macrophages. Since that time, several different cell types have been used to support intracellular L. pneumophila growth (1, 7, 17, 20, 24, 30) . In our experiments, human blood mononuclear cells supported logarithmic growth of L. pneumophila, although lymphocytes were predominant in the culture. Our monocyte concentration of 3 x 105 cells per ml yielded an L. pneumophila CFU/ml that was comparable to that determined by other investigators (17) .
Several factors are involved in intracellular L. pneumophila growth. Agar-passed strains of Legionella have been shown to reproduce less actively in human macrophages (20) . While unactivated human macrophages (18) and hydroxyl radical scavengers (20) allow improved intracellular Legionella survival and growth. The presence of antibiotics has variable effects on growth. Erythromycin (1, 7, 19, 30) , rifampin (7, 30) , ciprofloxacin (7) , pefloxacin (28) , gentamicin (1, 8, 30) , nalidixic acid (30), tetracycline (30) , and chloramphenicol (30) have each inhibited intracellular L. pneumophila growth under a variety of experimental conditions. Beta-lactam antibiotics such as ampicillin (30) , cefoxitin (30) , cefotaxime (30) , and thienamycin (8) have not been shown to inhibit intracellular L. pneumophila multiplication.
Results of this study support the theory that L. pneumophila can reproduce independently or in association with human monocytes and that antibiotics which remain in the extracellular space are not effective against intracellular pathogens. Rifampin (16, 21) , erythromycin (16, 21) , clindamycin (16, 21) , trimethoprim-sulfamethoxazole (12) , and ciprofloxacin (4) have been shown to be concentrated within human leukocytes. The uptake for clindamycin is quite pronounced, with intracellular concentrations being 20 to 50 times greater than extracellular concentrations (16) . This uptake may have allowed sub-MIC extracellular drug levels of clindamycin to achieve high enough intracellular concentrations to inhibit L. pneuimophila growth. Gentamicin was the only antibiotic with a low cellular/extracellular concentration ratio which effectively inhibited cell-associated Legionella growth. This could be explained by the fact that gentamicin was present at the time of bacterial inoculation and therefore inhibited phagocytosis (14) or had its effect before phagocytosis occurred. Our results with gentamicin are similar to those of Bacheson et al. (1) , who have shown that gentamicin effectively kills cell-associated L. pneumophila 2.5 h after bacterial inoculation (28) .
Since the quinolones were also present at the time of bacterial inoculation, a possible effect on phagocytosis cannot be completely excluded. In studies in which the effects of quinolones on leukocyte function were measured, increased macrophage phagocytic capacity has been demonstrated by pefloxacin (3). In contrast, lymphocyte studies with quinolones have shown reduced mitogen-induced cell proliferation (difloxacin) and decreased DNA synthesis with norfloxacin and difloxacin (2, 13) . The effect of each quinolones on leukocyte function could not be clearly defined in our model.
Ciprofloxacin, rosoxacin, enoxacin, and amifloxacin showed good activity against cell-associated L. pneumophila. Cinoxacin showed only moderate effects at 15 mg/ liter, which is its approximate peak level in serum. Ciprofloxacin at 3.0 mg/liter showed no detectable L. pneumophila associated with leukocytes. This result may be related to the fact that intracellular ciprofloxacin levels are approximately 2.5 times the extracellular levels (4) . Pefloxacin (28) and ofloxacin (25) have also been shown to inhibit intracellular L. pneumophila growth in similar in vitro models.
Vilde et al. (28) evaluated the extracellular concentration of six antibiotics that was necessary to inhibit intracellular growth of L. pneumophila for 24 h. They found at least a 90% decrease in intracellular CFU/ml for erythromycin (.0.05 mg/liter), rifampin (.0.005 mg/liter), pefloxacin (.0.06 mg/liter), trimethoprim-sulfamethoxazole (.0.1/0.5 mg/liter), and doxycycline (-0.8 mg/liter). Our model of L. pneumophila growth over 72 h gave similar results. Rifampin (0.1 mg/liter) and erythromycin (0.25 mg/liter) produced an approximate 4 log unit decrease in L. pneumophila growth. Each of these antibiotics was present at higher concentrations than those determined for 90% growth inhibition at 24 h. Conversely, antibiotics which were run at concentrations closer to those determined by Vilde et al. (28) to be necessary to inhibit growth (doxycycline at 0.4 mg/liter, trimethoprim-sulfamethoxazole at 0.15/2.9 mg/liter) were less effective (2.5 to 3 log unit decreases).
Some investigators have advocated the use of erythromycin-rifampin for serious Legionella infections. Based on our results with time kill curves, better killing of L. pneuimophila should occur with this combination than with either drug alone. Our results with the macrophage model, however, indicated no significant difference between the erythromycin-rifampin combination and either drug alone. Different Our results help to explain the in vitro and in vivo discrepancies of L. pneumophila susceptibility to beta-lactam antibiotics (23) . Also, our results support the use of the macrophage-L. pneumophila model to evaluate antimicrobial susceptibility testing of L. pneumophila.
Using this model, we have shown that several antibiotics, including many quinolone derivatives, inhibit monocyteassociated L. pneumophila growth. The role of these compounds in the treatment of human Legionella infections remains unclear, although their use as alternative agents in carefully selected patients seems possible.
